



June 1, 2006

Enzon Announces Exercise of Option to Purchase Additional Convertible Senior Notes

BRIDGEWATER, N.J., Jun 01, 2006 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that the lead initial purchaser in Enzon's recent private placement of \$225 million aggregate principal amount of its 4 percent Convertible Senior Notes due 2013 exercised its right, in full, to purchase an additional \$50 million aggregate principal amount of the notes. The notes are convertible at the option of the holder into shares of Enzon common stock at an initial conversion price of \$9.55 per share. The sale of the additional \$50 million in principal amount of notes is expected to close on June 5, 2006, subject to certain closing conditions. Enzon intends to use the net proceeds from the exercise of this option to acquire from time to time its outstanding 4 1/2% convertible subordinated notes due 2008.

The offering was made to certain qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended. The notes and shares of stock that may be issued upon conversion of the notes have not been registered under the Securities Act or any other state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities law.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology(TM) PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon also utilizes contract manufacturing opportunities to broaden its revenue base and enhance its organizational productivity. Enzon complements its internal research and development efforts with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. Further information about Enzon and this press release can be found on the Company's Web site at www.enzon.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 with respect to among other things, Enzon's plan for the offering and the use of the offering proceeds. These statements are subject to a number of factors and uncertainties that could cause actual events to differ materially from those contemplated in the forward-looking statements. Factors that could affect Enzon's ability to complete the contemplated transactions include among other things, the satisfaction or waiver of the conditions to the offering, the willingness of holders of the existing notes to resell those notes, legal considerations and material changes in the markets for debt and equity securities or the capital markets in general. Enzon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE: Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8759

Copyright Business Wire 2006

News Provided by COMTEX